Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013

Description: Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome).

- A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
AZX-100 - Drug Profile
entolimod - Drug Profile
beclomethasone dipropionate - Drug Profile
recilisib sodium - Drug Profile
BP-C2 - Drug Profile
Solulin - Drug Profile
GC-003 - Drug Profile
CLT-008 - Drug Profile
lovastatin - Drug Profile
MTP-131 - Drug Profile
NMIL12-1 - Drug Profile
MDY-1001 - Drug Profile
PLX-ARS - Drug Profile
BIO-300 - Drug Profile
BIO-300 - Drug Profile
BBT-015 - Drug Profile
BBT-007 - Drug Profile
Radiogardase - Drug Profile
AEOL-10150 + [filgrastim] - Drug Profile
APN-201 - Drug Profile
JP4-039 - Drug Profile
PLX-BMP - Drug Profile
pentoxifylline + [Vitamin E] - Drug Profile
Rx-100 - Drug Profile
VSEL for Radiation Exposure - Drug Profile
BIO-600 - Drug Profile
BIO-700 - Drug Profile
BIO-800 - Drug Profile
PrC-210 - Drug Profile
SY-303A - Drug Profile
granisetron - Drug Profile
Drug Against Radiation - Drug Profile
Apoptosis Inhibitors - Drug Profile
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics – Drug Profile Updates
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics – Discontinued Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics - Dormant Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products Under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2013
Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Development by Companies, H1 2013 (Contd
Number of Products under Development by Companies, H1 2013 (Contd
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Development by Companies, H1 2013 (Contd
Products under Development by Companies, H1 2013 (Contd
Products under Investigation by Universities/Institutes, H1 2013
Osiris Therapeutics, Inc., H1 2013
Gamida Cell Ltd., H1 2013
Nanotherapeutics, Inc., H1 2013
Maxygen, Inc., H1 2013
CEL-SCI Corporation, H1 2013
Aeolus Pharmaceuticals, Inc., H1 2013
Cleveland BioLabs, Inc., H1 2013
PAION AG, H1 2013
Soligenix, Inc., H1 2013
NeoStem, Inc., H1 2013
Pluristem Therapeutics Inc., H1 2013
SymBio Pharmaceuticals Limited, H1 2013
Cellerant Therapeutics, Inc., H1 2013
Humanetics Corporation, H1 2013
Meabco A/S, H1 2013
ProCertus BioPharm Inc., H1 2013
Onconova Therapeutics, Inc, H1 2013
Avaxia Biologics, Inc., H1 2013
Bolder Biotechnology, Inc., H1 2013
APEIRON Biologics AG, H1 2013
Biothera, H1 2013
Medisyn Technologies, Inc., H1 2013
ImmuneRegen BioSciences, Inc., H1 2013
Celtic Pharmaceutical Holdings L.P., H1 2013
Neumedicines Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics – Drug Profile Updates
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics – Discontinued Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics – Dormant Products
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Therapeutics – Dormant Products (Contd

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2013
Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Order by Fax - using the form below
Order by Post - print the order form below and send to
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2490867/
Office Code: SCD2SI81

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number: 833 130 83
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World